Sanofi (SNY) Stock
NASDAQ · SNY
40.99
Fundamentals
Market cap
$98.51B
Price / Earnings ratio
22.2x
Price / Sales ratio
1.8x
Price / Book ratio
1.3x
Return on assets
3.0%
Ex-Dividend date
4 May 2026
Last payment date
3 Jun 2026
Dividend amount
$1.77
Dividend yield
4.30%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
NeutralSNYSeptember 25, 2026
Zacks Investment ResearchNeutral
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY

Reuters
European drugmakers call for faster trials, more spending to compete with US, China
NeutralSNYSeptember 22, 2026
ReutersNeutral
European drugmakers call for faster trials, more spending to compete with US, China
SNY

MarketBeat
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
NeutralSNYSeptember 22, 2026
MarketBeatNeutral
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
SNY

MarketBeat
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
NeutralSNYSeptember 20, 2026
MarketBeatNeutral
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
SNY
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
66B44B22B0
Debt & Balance Sheet
Total assets
Total liabilities
2025
152B100B50B0
Revenue to Profit
2025$55.0B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$7.8B
Net incomeEarnings
EPS forecast
Actual EPS
$0.90
$0.96
Q2FY25
$1.70
$1.60
Q3FY25
$0.85
Q4FY25
$1.08
Q1FY26
$1.11
Q2FY26
The market is expecting earnings per share of $1.11 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
NeutralSNYSeptember 25, 2026
Zacks Investment ResearchNeutral
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY

Reuters
European drugmakers call for faster trials, more spending to compete with US, China
NeutralSNYSeptember 22, 2026
ReutersNeutral
European drugmakers call for faster trials, more spending to compete with US, China
SNY

MarketBeat
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
NeutralSNYSeptember 22, 2026
MarketBeatNeutral
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
SNY

MarketBeat
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
NeutralSNYSeptember 20, 2026
MarketBeatNeutral
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
SNY

MarketBeat
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
NeutralSNYSeptember 10, 2026
MarketBeatNeutral
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
SNY

Stocktwits
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
NeutralSNYAugust 28, 2026
StocktwitsNeutral
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
SNY

Zacks Investment Research
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
NeutralSNYAugust 28, 2026
Zacks Investment ResearchNeutral
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
SNY

Reuters
US FDA approves updated COVID vaccines for 2026-27 season
NeutralSNYAugust 27, 2026
ReutersNeutral
US FDA approves updated COVID vaccines for 2026-27 season
SNY

The Motley Fool
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
NeutralSNYAugust 26, 2026
The Motley FoolNeutral
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
SNY

Stocktwits
PFE, MRK, SNY, MRNA In Focus As Trump Reportedly Eyes Executive Order On Vaccines And Autism
NeutralSNYAugust 6, 2026
StocktwitsNeutral
PFE, MRK, SNY, MRNA In Focus As Trump Reportedly Eyes Executive Order On Vaccines And Autism
SNY
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
SectorHealthcare
IndustryDrug Manufacturers - General
Employees74,846
CEOMs. Belen Garijo Lopez M.D.
IPO DateJul 1, 2002
HeadquartersParis, France
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Belen Garijo Lopez M.D. | CEO & Director | 1960 |
| Mr. François-Xavier Roger | Executive VP & CFO | 1962 |
| Dr. Michael Quigley Ph.D. | Chief Scientific Officer & Head of Research | — |
| Mr. Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | 1974 |
| Ms. Jamie Haney | Executive VP & General Counsel | — |
| Mr. Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 1957 |
| Ms. Veronique Jaillet | Executive VP & Interim Chief People Officer | — |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | — |
| Mr. Erik Wallström | Head of Therapeutic Area - Neurology Development | — |
| Mr. Thomas Triomphe | Executive Vice President of Vaccines | 1974 |
Fundamentals
Valuation
Market cap$98.51B
Price-to-sales ratio1.80
Price-to-book value1.27
Price-earnings ratio22.20
Return on Equity6.00%
Return on Sales12.00%
Return on Assets3.00%
PEG ratio28.63
Earnings Per Share
Earnings Per Share$1.87
Income Statement
Average volume2,324,762
EBITDA$14.33B
1 year high (52w)$52.68
1 year low (52w)$40.89
Dividend
Ex dividend date4 May 2026
Dividend amount$1.77
Dividend yield4.30%
Last payment date3 Jun 2026
Dividend yield (TTM)5.90%
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.3 | +5.3 | -7.3 | +4.2 | ||||||||
| 2022 | +2.6 | +1.6 | +0.5 | +0.1 | +0.4 | -6.0 | -2.6 | -16.1 | -5.9 | +10.3 | +5.5 | +5.6 |
| 2023 | +0.3 | -3.9 | +15.7 | -1.0 | -4.5 | +6.8 | -0.5 | +0.2 | +1.0 | -15.5 | +0.9 | +6.4 |
| 2024 | -0.2 | -1.2 | +2.8 | +1.9 | -2.0 | -1.5 | +4.5 | +8.9 | +0.2 | -7.7 | -9.0 | +0.6 |
| 2025 | +12.8 | +2.1 | -1.9 | +1.1 | -8.7 | -1.8 | -7.0 | +5.8 | -4.8 | +1.6 | -0.3 | -3.0 |
| 2026 | -2.5 | +2.9 | +1.1 | -2.4 | -5.2 | -0.7 | +3.5 | +3.3 | -7.3 |
Corporate actions
Upcoming
No upcoming corporate actions for SNY
Past
DividendQ2/26
Ex-dividend date4 May 2026
Payable date3 Jun 2026
Amount per share$2.42
DividendQ2/25
Ex-dividend date9 May 2025
Payable date12 Jun 2025
Amount per share$2.21
DividendQ2/23
Ex-dividend date30 May 2023
Payable date23 Jun 2023
Amount per share$1.90
DividendQ2/22
Ex-dividend date4 May 2022
Payable date8 Jun 2022
Amount per share$1.80



